Pentabromoethylbenzene
(PBEB), as one of the novel brominated flame
retardants (NFBRs), has caused increasing public concern for health
risks. Till now, information regarding potential effects of PBEB on
thyroid function remains unclear. Herein, we investigated thyroid
disruption of PBEB in vitro and in silico and evaluated thyroid dysfunction induced by PBEB using Sprague–Dawley
rats. PBEB showed thyroid receptor (TR) β antagonistic activity
with IC50 of 9.82 × 10–7 M in the
dual-luciferase reporter gene assay and induced relative reorientation
of helix 11 (H11) and H12 of the TR ligand binding domain as revealed
by molecular dynamics simulations. PBEB (0.2, 2, 20 mg/kg BW/d) markedly
altered the transcriptome profile of thyroid with induction of 17,
42, and 119 differentially expressed genes (DEGs) involved in thyroid
hormone signaling and synthesis pathway, of which transthyretin and albumin are common DEGs. The 28-d exposure
to PBEB significantly decreased the triiodothyronine level (from 7.23
to 5.67 ng/mL) and increased the thyrotropin level (from 7.88 to 12.86
mU/L) for female rats. PBEB consequently reduced thyroid weight and
altered its morphology with more depleted follicles. Overall, our
study provides the first account of evidence on PBEB exerted thyroid
disruption, transcriptome aberration, and morphological alteration,
facilitating health risk assessment of PBEB and structurally related
NBFRs.